Caribou Biosciences, Inc. Net Change in Cash
Caribou Biosciences, Inc. (CRBU) reported Net Change in Cash of $13.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-13
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$303.00K, a 102.31% decline year-over-year.
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $13.12M.
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$1.76M.
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$5.59M.
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$3.93M.
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$34.87M.
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$7.18M.
- Caribou Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$182.08M, a 181.10% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.79M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$303.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$3.93M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$5.15M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $8.91M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $13.12M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$34.87M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$19.19M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$13.30M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$1.76M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$7.18M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $45.72M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $7.86M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$5.59M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$182.08M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | -$158.34M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$128.27M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$92.79M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $224.51M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $419.40M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $113.62M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $129.97M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$25.12M 10-K · filed 2022-03-21 | |||
| 2020-09-30 | -$16.52M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | -$7.94M 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | -$4.60M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |